
Opinion|Videos|June 26, 2024
Use of Biologics in Pediatric Patients and Conversations with Parents
Robert Sporter, MD, discusses the initial conversations he has with pediatric patients and their parents when considering biologic therapies, addressing the risks associated with not treating the condition, such as compromised lung function and increased steroid use. He emphasizes the importance of communicating a comprehensive treatment plan, including contingencies for cases where a particular therapy may not be effective.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed
3
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
4
Why Mentorship Matters Most for Dermatology Trainees
5








































































